November 2009
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 | |
|
Multaq Sanctioned for Heart Rhythm Disorders
Atrial fibrillation or atrial flutter
Thu Jul 02, 2009, 10:58
|
Story Tools
|
|
•
|
Printable
version
|
|
•
|
Jul 02, 2009 News
|
|
Related News Categories
| | • | Heart / Stroke-Related: Misc | | • | Food & Drug Administration | | • | Drug Approvals |
Related News
| • | Common Infections May Contribute to Strokes - Nov 10, 2009 | • | Stroke Puts Stress on Spousal Relationship - Nov 10, 2009 | • | No Gender Gap Found for Clot-Busting Drug - Nov 09, 2009 | • | Obesity Seems to Alter Heart Structure - Nov 09, 2009 | • | Istodax Approved for Cutaneous T-Cell Lymphoma - Nov 06, 2009 | • | Phosphorus Levels May Predict Heart Disease - Nov 05, 2009 | • | Genes Linked to 'Pot' Belly - Nov 05, 2009 | • | FDA Initiative Seeks to Reduce Accidental Overdoses - Nov 04, 2009 | • | FDA Issues Warning for Diabetes Drug - Nov 03, 2009 | • | Statins May Worsen Fatigue in Heart Failure Patients - Nov 03, 2009 | • | Stroke Centers May Offer Best Shot at Recovery - Oct 29, 2009 | • | Arzerra Approved for Chronic Lymphocytic Leukemia - Oct 27, 2009 | • | Migraine With Aura Can Double Stroke Risk - Oct 28, 2009 | • | All New Dialysis Patients at Increased Risk of Death - Oct 27, 2009 | • | Heart Disease Gender Gap Narrows - Oct 26, 2009 |
THURSDAY, July 2 (HealthDay News) -- Multaq (dronedarone) tablets have been approved by the U.S. Food and Drug Administration to promote a normal heart rhythm in people with atrial fibrillation or atrial flutter. These conditions cause the heart to beat too quickly and can prevent it from pumping blood correctly.
The drug's label, however, will contain a "black box" warning that the medication could cause deadly reactions in people with recent severe heart failure, the agency said Thursday in a news release.
In clinical testing involving more than 4,000 people, Multaq lowered the rates of cardiac hospitalization or death from any cause by 24 percent, compared to an inactive placebo, the FDA said. The most common side effects were diarrhea, nausea, vomiting, fatigue and weakness.
Multaq is produced by French drug maker Sanofi-Aventis.
More information
The FDA has more about this approval.
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Today's Top News Stories | • | Clinical Trials Update: Nov. 10, 2009 - Nov 10, 2009, 09:37
- Psoriasis
- Osteoporosis
- Hypertension
| • | Common Infections May Contribute to Strokes - Nov 10, 2009, 12:00
But researchers not exactly sure how pathogens raise risk of brain attack. | • | Teen Obesity Ups MS Risk in Women - Nov 10, 2009, 09:00
Researchers suspect lower vitamin D levels may be to blame.
| • | Stroke Puts Stress on Spousal Relationship - Nov 10, 2009, 12:00
Patient/caregiver roles often take the place of a partnership, researchers say. | • | Early Use of NSAIDs Might Prevent Alzheimer's - Nov 10, 2009, 09:00
Study in mice finds anti-inflammatories don't help those with existing disease. |
|
|
|
